The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 707-713

  Sun, Dian Shui ^a   Zhao, Miao Qing ^b   Xia, Ming ^c   Li, Li ^c   Jiang, Yu Hua ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Foxp3; Head and neck cancers; Regulatory T cell

Indexed keywords

CYCLOOXYGENASE 2; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; CANCER STAGING; ENZYME IMMUNOASSAY; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 84866286285     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9903-2     Document Type: Article

References (32)

1. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3-21.
2. Lang S, Zeidler R. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol. 2003;16(2):41-8.
3. Baratelli F, et al. Prostaglandin E2 induces Foxp3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005;175:1483-9.
4. Hiraoka N, Onozato K, Kosuge T Hirohashi S. Prevalence of Foxp3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-34.
5. Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9.
6. Shimizu K, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585-90.
7. Jonuleit H, et al. Identification and functional characterization of human CD4+ CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-94.
8. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+ CD25+ regulatory T cells. Semin Immunol. 2004;16:89-98.
9. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol. 2006;176:4622-31.
10. Ito T, et al. Two functional subsets of Foxp3+ regulatory T cells in human thymus and periphery. Immunity. 2008;28:870-80.
11. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008;20:241-6.
12. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19:217-23.
13. Ling KL, et al. Increased frequency of regulatory T cells in peripheral blood and tumour-infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 2007;7:7.
14. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-11.
15. O'Mahony CA, et al. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis. Surgery. 1999;126(2):364-70.
16. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 2000;6:2424-30.
17. Dannenberg AJ, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544-51.
18. Chan G, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59:991-4.
19. Saba NF, et al. Role of COX-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009;2(9):823-9.
20. Kyzas PA, Stefanou D, Agnantis NJ. COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol. 2005;18(1):153-60.
21. Chang BW, et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2004;10(5):1678-84.
22. Sharma S, et al. Tumor cyclooxygenase-2/prostaglandin E2- dependent promotion of Foxp3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65: 5211-20.
23. Huang M, et al. Non-small cell lung cancer cyclooxygenase-2- dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58:1208-16.
24. Gately S, Li WW. Multiple role of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004;31:2-11.
25. Costa C, et al. Cyclooxygenase-2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429-534.
26. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J Biol Chem. 2001;276(52):48997-9002.
27. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des. 2004;10:647-57.
28. Yang L, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111:727-35.
29. Sharma S, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003;9:961-8.
30. Li JF, Chu YW, Wang GM. The prognostic value of peritumonal regulatory T cells and its correlation with intratumoral cyclooxygenese- 2 exprssion in clear cell renal cell carcinoma. BJU Int. 2008;103:399-405.
31. Edelman MJ, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib+ chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008;26:848-55.
32. Lissoni P, et al. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 2009;29(5): 1847-52.